A wave of cannabis-focused pharmaceutical companies is gaining renewed momentum as regulatory changes in the United States reshape the investment landscape. Following the federal government’s move to reclassify cannabis under a less restrictive schedule, biotech firms developing cannabis-derived and cannabinoid-based medicines are attracting fresh capital, revisiting public l...
Click on the "Follow" button below and you'll get the latest news from Kind Green Buds via email, mobile or you can read them on your personal news page on this site.
You can unsubscribe anytime you want easily.
You can also choose the topics or keywords that you're interested in, so you receive only what you want.
Kind Green Buds title: Kind Green Buds